高h肉辣文交换_好吊妞视频haodiaoniucom_羞羞漫画登录页面免费入口_美国一级片视频

最近搜索:細胞培養 微生物學 分子生物 生物化學
首頁>>免疫學>>一抗>>磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
  • 產品貨號:
    BN42097R
  • 中文名稱:
    磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
  • 英文名稱:
    Rabbit anti-phospho-JAK2 (Tyr1007+Tyr1008) Monoclonal antibody
  • 品牌:
    Biorigin
  • 貨號

    產品規格

    售價

    備注

  • BN42097R-50ul

    50ul

    ¥2020.00

    交叉反應:Human,Mouse,Rat(predicted:Chicken,Pig,Rabbit) 推薦應用:IHC-P,IHC-F,ICC,IF

  • BN42097R-100ul

    100ul

    ¥3240.00

    交叉反應:Human,Mouse,Rat(predicted:Chicken,Pig,Rabbit) 推薦應用:IHC-P,IHC-F,ICC,IF

產品描述

英文名稱phospho-JAK2 (Tyr1007+Tyr1008)
中文名稱磷酸化蛋白酪氨酸激酶JAK-2重組兔單克隆抗體
別    名JAK2(Y1007+Y1008); JAK2 (phospho Y1007); p-JAK2 (phospho Y1007); JAK2 (phospho Y1007 + Y1008); p-JAK2 (phospho Y1007 + Y1008); JAK2(Phospho-Tyr1007/1008); Tyrosine protein kinase JAK2; JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating Kinase 2; Janus Kinase 2; JTK 10; JTK10; OTTHUMP00000043260; Tyrosine-protein kinase JAK2; Tyrosine protein kinase JAK2.  
產品類型磷酸化抗體 
研究領域腫瘤  細胞生物  染色質和核信號  信號轉導  激酶和磷酸酶  表觀遺傳學  
抗體來源Rabbit
克隆類型Monoclonal
克 隆 號6E5
交叉反應Human, Mouse, Rat,  (predicted: Chicken, Pig, Rabbit, )
產品應用IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50 IF=1:50-200 (石蠟切片需做抗原修復)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量131kDa
細胞定位細胞核 細胞漿 細胞膜 
性    狀Liquid
濃    度1mg/ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human JAK2 around the phosphorylation site of Tyr1007/1008:KE(p-Y)(p-Y)KV 
亞    型IgG
純化方法affinity purified by Protein A
儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
PubMedPubMed
產品介紹JAK2 (Janus Activating Kinase 2) is a tyrosine kinase of the non-receptor type, that associates with the intracellular domains of cytokine receptors; JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin; it has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. Ligand binding to a variety of cell surface receptors (e.g., cytokine, growth factor, GPCRs) leads to an association of those receptors with JAK proteins, which are then activated via phosphorylation on tyrosines 1007 and 1008 in the kinase activation loop. Activated JAK proteins phosphorylate and activate STAT (signal transducers and activators of transcription) proteins, which then dimerize and translocate to the nucleus. Once in the nucleus, STAT proteins bind to DNA and modify the transcription of various genes.

Function:
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.

Subunit:
Interacts with EPOR, LYN, SIRPA, SH2B1 and TEC. Interacts with IL23R, SKB1 and STAM2.

Subcellular Location:
Endomembrane system; Peripheral membrane protein. Cytoplasm. Nucleus.

Tissue Specificity:
Ubiquitously expressed throughout most tissues.

Post-translational modifications:
Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity. Also phosphorylated by TEC.

DISEASE:
Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BDCHS) [MIM:600880]. A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.

Similarity:
Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.

SWISS:
O60674

Gene ID:
3717

Database links:

Entrez Gene: 3717 Human

Entrez Gene: 16452 Mouse

Entrez Gene: 24514 Rat

GenBank: NP_004963 Human

Omim: 147796 Human

SwissProt: O60674 Human

SwissProt: Q62120 Mouse

SwissProt: Q62689 Rat

Unigene: 656213 Human

Unigene: 275839 Mouse

Unigene: 18909 Rat



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications